2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

Abstract Number: 107

Targeting Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Real-World Emapalumab Experience Spanning 3 Years
Abstract Number: 109

Tarsitis in Juvenile Idiopathic Arthritis: Clinical characteristics, imaging features, and treatment Response – A multicenter retrospective study
Abstract Number: 071

The Association Between Age at Diagnosis and Health-Related Quality of Life in Takayasu Arteritis
Abstract Number: 069

The Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis trial: Baseline cohort characteristics and importance of stakeholder partner-informed knowledge translation and exchange
Abstract Number: 135

The Blood-CSF-Barrier in SLE: Volume and Blood Flow of the Choroid Plexus and Periventricular Tissue Abnormality Gradients
Abstract Number: 123

The Details Matter: A Patient Centered Approach to Overcoming Barriers in a Pediatric to Adult Rheumatology Transition Clinic
Abstract Number: 050

The Quiet Beginning: Early Pediatric Systemic Lupus Erythematosus (SLE) Without Nephritis and the Path to Renal Involvement
Abstract Number: 081

Therapeutic Drug Monitoring in Pediatric Rheumatology: A Survey of Providers in North America
Abstract Number: 024

Therapeutic Plasma Exchange in Pediatric Autoimmune Encephalitis
Abstract Number: 074

Tissue Protein Expression Profiling of Interferon Gamma and Frizzled-Wnt-related Signaling Show Increased Periadnexal and Perivascular Localization in Juvenile Localized Scleroderma Skin
Abstract Number: 136

Transcriptomic Analysis of Ultrasound-Guided Synovial Biopsies from Patients with Juvenile Idiopathic Arthritis
Abstract Number: 026

Treatment strategies for articular flares in JIA patients receiving biologic therapy
Abstract Number: 092

Treatment-Refractory Juvenile Idiopathic Arthritis: Clinical Features and Biologic/Targeted Synthetic DMARD Utilization Patterns in a Single-Center Cohort
Abstract Number: 128

Trends in Medicaid Enrollment Churn Among Children with Rheumatic Disease Diagnoses, 2018-2023

Jump to: View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].